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Many patients in this sample don't achieve HbA 1c -therapy-goals and many don't test their blood glucose. Less than 1 in 5 patients performs the recommended test frequency. In IIT SMBG is needed to support insulin dose adjustments: only 1 in 50 tests enough. In CT patients the differences in HbA 1c between testers and non-testers are largest. Lacking SMBG benefit in IIT treated patients might indicate the insufficiency of current testing. The new guideline might help to close these gaps. Further research is needed to monitor benefits resulting from the implementation of the Indian guideline on glucose monitoring in diabetes therapy. ). The necessary testing frequency is based on the specific therapeutic approach as well as the individual ability of patients to make best use of SMBG information for therapy and lifestyle adjustments. Drugs that can cause hypoglycemia (e.g. sulfonylureas, insulin) do require SMBG for safety reasons. Furthermore, any insulin therapy with a flexible insulin dosing scheme does require frequent SMBG for adequate insulin dose determination to support a safe and effective therapy. 5, 6 SMBG test frequencies correlate with the quality of glycemic control.
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SMBG is reimbursed in many healthcare systems -in particular in combination with insulin therapy. Individual affordability of SMBG, e.g. in case of non-reimbursement or co-payments, impairs the adherence to recommended test frequencies. Figure 2 shows the HbA 1c levels by different therapy segments and bG meter availability. HbA 1c levels are by 0.3 %, 0.2 %, 1.1% and 0.0 % lower in SMBG users in the OAD, BOT, CT and IIT segment.
1,180 patients (52.4 %) have a meter for SMBG home-testing. However 151 (12.8%) of these report that they do not test at home. Figure 2 provides the share of testers by therapy group.
In 2014 an Indian guideline on glycemic monitoring was published.
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This study aims to assess the level of SMBG usage in patients on different diabetes therapies. It also explores the correlation of SMBG usage with glycemic control as measured by HbA 1c .
Source data for this explorative analysis is the CSD-PDS Diabetes survey (Cegedim Strategic Data -Patient Data Study) covering drug treated patients with diabetes. All 2,250 cases were documented in the 2 nd half year 2013. PDS Diabetes is a syndicated research with a fixed representative panel of diabetologists, cardiologists and GPs from larger Indian cities using a standardized documentation of cases. SMBG usage is analyzed by therapeutic subgroups: oral anti-diabetic therapy (OAD 75.2%, no insulin use), basal supported oral therapy (BOT 9.5%, OAD being supplemented by either long acting insulin, NPH insulin or premixed insulin), conventional insulin therapy (CT 7.9%, no OADs used), intensive insulin therapy (IIT 4.8%, no OADs used, multi dose insulin therapy, mostly involving short acting insulin) and others (2.8%). 
